{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:02:18Z","timestamp":1753894938434,"version":"3.41.2"},"reference-count":37,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To identify factors associated with willingness to participate in a COVID-19 clinical trial and reasons for and against participating.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            We surveyed Massachusetts (MA, USA)\u00a0residents online using the Dynata survey platform and via phone using random digit dialing between October and\u00a0November 2021. Respondents were asked to imagine they were hospitalized with COVID-19 and invited to participate in a treatment trial. We assessed willingness to participate by asking, \u201cWhich way are you leaning\u201d and why. We used multivariate logistic regression to model factors associated with leaning toward participation. Open-ended responses were analyzed using conventional content analysis.\n            <jats:bold>Results:<\/jats:bold>\n            Of 1071 respondents, 65.6% leaned toward participating. Multivariable analyses revealed college-education (OR: 1.59; 95% CI: 1.11, 2.27), trust in the healthcare system (OR: 1.32; 95% CI: 1.10, 1.58) and relying on doctors (OR: 1.77; 95% CI: 1.45, 2.17) and family or friends (OR: 1.31; 95% CI: 1.11, 1.54) to make health decisions were significantly associated with leaning toward participating. Respondents with lower health literacy (OR: 0.57; 95% CI: 0.36, 0.91) and who identify as Black (OR: 0.40; 95% CI: 0.24, 0.68), Hispanic (OR: 0.61; 95% CI: 0.38, 0.98), or republican (OR: 0.61; 95% CI: 0.38, 0.97) were significantly less likely to lean toward participating. Common reasons for participating included helping others, benefitting oneself and deeming the study low risk. Common reasons for leaning against were deeming the study high risk, disliking experimental treatments and not wanting to be a guinea pig.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Our finding that vulnerable individuals and those with lower levels of trust in the healthcare system are less likely to be receptive to participating in a COVID-19 clinical trial highlights that work is needed to achieve a healthcare system that provides confidence to historically disadvantaged groups that their participation in research will benefit their community.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0181","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T10:39:38Z","timestamp":1721817578000},"source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 clinical trials: who is likely to participate and why?"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-3457","authenticated-orcid":false,"given":"Kimberly A","family":"Fisher","sequence":"first","affiliation":[{"name":"Division of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA\u00a001655, USA"},{"name":"Division of Pulmonary &amp; Critical Care Medicine, Department of Medicine, UMass Chan Medical School, Worcester, MA\u00a001655, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara M","family":"Epstein","sequence":"additional","affiliation":[{"name":"Division of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA\u00a001655, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngoc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA\u00a001655, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Fouayzi","sequence":"additional","affiliation":[{"name":"Division of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA\u00a001655, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybil","family":"Crawford","sequence":"additional","affiliation":[{"name":"Tan Chingfen Graduate School of Nursing, UMass Chan Medical School, Worcester, MA\u00a001655, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P","family":"Linas","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, &amp; Boston University School of Public Health, Boston, MA\u00a002118,\u00a0USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M","family":"Mazor","sequence":"additional","affiliation":[{"name":"Division of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA\u00a001655, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_8_3_2","unstructured":"NIH Revitalization Act Subtitle B Part 1 Sec 131\u2013133 June 10 1993. https:\/\/orwh.od.nih.gov\/sites\/orwh\/files\/docs\/NIH-Revitalization-Act-1993.pdf (2023)."},{"volume-title":"Dept of Health and Human Services, ed2014","author":"Food and Drug Administration","key":"e_1_3_8_4_2","unstructured":"Food and Drug Administration. FDA action plan to enhance the collection and availability of demographic subgroup data. In: Dept of Health and Human Services, ed2014. https:\/\/www.fda.gov\/media\/89307\/download"},{"volume-title":"Dept of Health and Human Services, ed2022","author":"Food and Drug Administration","key":"e_1_3_8_5_2","unstructured":"Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; Draft guidance for industry; Availability. In: Dept of Health and Human Services, ed2022. Docket number FDA-2021-D-0789. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations"},{"issue":"11","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"e2133205","DOI":"10.1001\/jamanetworkopen.2021.33205","article-title":"Racial and ethnic disparities among participants in precision oncology clinical studies","volume":"4","author":"Aldrighetti CM","year":"2021","unstructured":"Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw. Open 4(11), e2133205 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree JM","year":"2019","unstructured":"Loree JM, Anand S, Dasari A Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 5(10), e191870 (2019).","journal-title":"JAMA Oncol."},{"issue":"10","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamacardio.2018.2559","article-title":"Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review","volume":"3","author":"Tahhan AS","year":"2018","unstructured":"Tahhan AS, Vaduganathan M, Greene SJ Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol. 3(10), 1011\u20131019 (2018).","journal-title":"JAMA Cardiol."},{"issue":"9","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.hlc.2022.06.668","article-title":"Inclusion of under-represented racial and ethnic groups in cardiovascular clinical trials","volume":"31","author":"Vilcant V","year":"2022","unstructured":"Vilcant V, Ceron C, Verma G, Zeltser R, Makaryus AN. Inclusion of under-represented racial and ethnic groups in cardiovascular clinical trials. Heart Lung Circ. 31(9), 1263\u20131268 (2022).","journal-title":"Heart Lung Circ."},{"key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neubiorev.2019.03.020","article-title":"Race reporting and disparities in clinical trials on Alzheimer's disease: a systematic review","volume":"101","author":"Canevelli M","year":"2019","unstructured":"Canevelli M, Bruno G, Grande G Race reporting and disparities in clinical trials on Alzheimer's disease: a systematic review. Neurosci. Biobehav. Rev. 101, 122\u2013128 (2019).","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"e2037640","DOI":"10.1001\/jamanetworkopen.2020.37640","article-title":"Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials","volume":"4","author":"Flores LE","year":"2021","unstructured":"Flores LE, Frontera WR, Andrasik MP Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials. JAMA Netw. Open 4(2), e2037640 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamainternmed.2022.5600","article-title":"Sex, racial, and ethnic representation in COVID-19 clinical trials: a systematic review and meta-analysis","volume":"183","author":"Xiao H","year":"2023","unstructured":"Xiao H, Vaidya R, Liu F, Chang X, Xia X, Unger JM. Sex, racial, and ethnic representation in COVID-19 clinical trials: a systematic review and meta-analysis. JAMA Intern. Med. 183(1), 50\u201360 (2023).","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1353\/hpu.0.0323","article-title":"More than Tuskegee: understanding mistrust about research participation","volume":"21","author":"Scharff DP","year":"2010","unstructured":"Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J. Health Care Poor Underserved 21(3), 879\u2013897 (2010).","journal-title":"J. Health Care Poor Underserved"},{"issue":"4","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1200\/JCO.2004.03.160","article-title":"Enrollment of African Americans onto clinical treatment trials: study design barriers","volume":"22","author":"Adams-Campbell LL","year":"2004","unstructured":"Adams-Campbell LL, Ahaghotu C, Gaskins M Enrollment of African Americans onto clinical treatment trials: study design barriers. J. Clin. Oncol. 22(4), 730\u2013734 (2004).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2288-14-42","article-title":"Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups","volume":"14","author":"Bonevski B","year":"2014","unstructured":"Bonevski B, Randell M, Paul C Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups. BMC Med. Res. Methodol. 14, 42 (2014).","journal-title":"BMC Med. Res. Methodol."},{"issue":"2","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.2105\/AJPH.2013.301706","article-title":"A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders","volume":"104","author":"George S","year":"2014","unstructured":"George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am. J. Public Health 104(2), e16\u201331 (2014).","journal-title":"Am. J. Public Health"},{"issue":"3","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/djaa155","article-title":"\u201cWhen offered to participate\u201d: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","volume":"113","author":"Unger JM","year":"2021","unstructured":"Unger JM, Hershman DL, Till C \u201cWhen offered to participate\u201d: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. J. Natl Cancer Inst. 113(3), 244\u2013257 (2021).","journal-title":"J. Natl Cancer Inst."},{"issue":"3","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40615-020-00839-y","article-title":"Willingness to participate in health research among community-dwelling middle-aged and older adults: does race\/ethnicity matter?","volume":"8","author":"Milani SA","year":"2021","unstructured":"Milani SA, Swain M, Otufowora A, Cottler LB, Striley CW. Willingness to participate in health research among community-dwelling middle-aged and older adults: does race\/ethnicity matter? J. Racial Ethn. Health Disparities 8(3), 773\u2013782 (2021).","journal-title":"J. Racial Ethn. Health Disparities"},{"issue":"9","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"e2127792","DOI":"10.1001\/jamanetworkopen.2021.27792","article-title":"Demographic and health behavior factors associated with clinical trial invitation and participation in the United States","volume":"4","author":"Williams CP","year":"2021","unstructured":"Williams CP, Senft Everson N, Shelburne N, Norton WE. Demographic and health behavior factors associated with clinical trial invitation and participation in the United States. JAMA Netw. Open 4(9), e2127792 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"42","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.15585\/mmwr.mm6942e1","article-title":"Race, ethnicity, and age trends in persons who died from COVID-19 - United States, May-August 2020","volume":"69","author":"Gold JAW","year":"2020","unstructured":"Gold JAW, Rossen LM, Ahmad FB Race, ethnicity, and age trends in persons who died from COVID-19 - United States, May-August 2020. MMWR Morb. Mortal. Wkly Rep. 69(42), 1517\u20131521 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"1","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamainternmed.2020.3857","article-title":"Assessment of COVID-19 hospitalizations by race\/ethnicity in 12 States","volume":"181","author":"Karaca-Mandic P","year":"2021","unstructured":"Karaca-Mandic P, Georgiou A, Sen S. Assessment of COVID-19 hospitalizations by race\/ethnicity in 12 States. JAMA Intern. Med. 181(1), 131\u2013134 (2021).","journal-title":"JAMA Intern. Med."},{"issue":"42","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.15585\/mmwr.mm6942e2","article-title":"Excess deaths associated with COVID-19, by age and race and ethnicity - United States, January 26-October 3, 2020","volume":"69","author":"Rossen LM","year":"2020","unstructured":"Rossen LM, Branum AM, Ahmad FB, Sutton P, Anderson RN. Excess deaths associated with COVID-19, by age and race and ethnicity - United States, January 26-October 3, 2020. MMWR Morb. Mortal. Wkly Rep. 69(42), 1522\u20131527 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"15","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospilatization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1\u201330, 2020","volume":"69","author":"Garg S","year":"2020","unstructured":"Garg S, Kim L, Whitaker M Hospilatization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1\u201330, 2020. MMWR Morb. Mortal. Wkly Rep. 69(15), 458\u2013464 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"3","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.15585\/mmwr.mm7103e1","article-title":"Racial and ethnic disparities in receipt of medications for treatment of COVID-19 - United States, March 2020-August 2021","volume":"71","author":"Wiltz JL","year":"2022","unstructured":"Wiltz JL, Feehan AK, Molinari NM Racial and ethnic disparities in receipt of medications for treatment of COVID-19 - United States, March 2020-August 2021. MMWR Morb. Mortal. Wkly Rep. 71(3), 96\u2013102 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"43","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","article-title":"Racial and ethnic disparities in outpatient treatment of COVID-19 - United States, January-July 2022","volume":"71","author":"Boehmer TK","year":"2022","unstructured":"Boehmer TK, Koumans EH, Skillen EL Racial and ethnic disparities in outpatient treatment of COVID-19 - United States, January-July 2022. MMWR Morb. Mortal. Wkly Rep. 71(43), 1359\u20131365 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"9","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh HF","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual. Health Res. 15(9), 1277\u20131288 (2005).","journal-title":"Qual. Health Res."},{"issue":"2","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1037\/0033-2909.86.2.307","article-title":"In-group bias in the minimal intergroup situation: a cognitive-motivation analysis","volume":"86","author":"Brewer MB","year":"1979","unstructured":"Brewer MB. In-group bias in the minimal intergroup situation: a cognitive-motivation analysis. Psychol. Bull. 86(2), 307\u2013324 (1979).","journal-title":"Psychol. Bull."},{"key":"e_1_3_8_28_2","first-page":"86","volume-title":"Prosocial Behavior.","author":"Dovidio JF","year":"1991","unstructured":"Dovidio JF, Piliavin JA, Gaertner SL, Schroeder DA, Clark RD III. The arousal: cost-reward and the process of intervention: a review of the evidence. In: Prosocial Behavior. Clark MS (Ed.). 86\u2013118 (1991)."},{"issue":"4","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0146167204271651","article-title":"Identity and emergency intervention: how social group membership and inclusiveness of group boundaries shape helping behavior","volume":"31","author":"Levine M","year":"2005","unstructured":"Levine M, Prosser A, Evans D, Reicher S. Identity and emergency intervention: how social group membership and inclusiveness of group boundaries shape helping behavior. Pers. Soc. Psychol. Bull. 31(4), 443\u2013453 (2005).","journal-title":"Pers. Soc. Psychol. Bull."},{"issue":"8","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"e0136874","DOI":"10.1371\/journal.pone.0136874","article-title":"Affective balance, team prosocial efficacy and team trust: a multilevel analysis of prosocial behavior in small groups","volume":"10","author":"Cuadrado E","year":"2015","unstructured":"Cuadrado E, Tabernero C. Affective balance, team prosocial efficacy and team trust: a multilevel analysis of prosocial behavior in small groups. PLOS ONE 10(8), e0136874 (2015).","journal-title":"PLOS ONE"},{"issue":"1","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1037\/0022-3514.92.1.56","article-title":"Social exclusion decreases prosocial behavior","volume":"92","author":"Twenge JM","year":"2007","unstructured":"Twenge JM, Baumeister RF, DeWall CN, Ciarocco NJ, Bartels JM. Social exclusion decreases prosocial behavior. J. Pers. Soc. Psychol. 92(1), 56\u201366 (2007).","journal-title":"J. Pers. Soc. Psychol."},{"issue":"5","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1371\/journal.pmed.0050091","article-title":"Communicating the results of clinical research to participants: attitudes, practices, and future directions","volume":"5","author":"Shalowitz DI","year":"2008","unstructured":"Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med. 5(5), e91 (2008).","journal-title":"PLoS Med."},{"issue":"8","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jech.2007.067645","article-title":"Integrating research and action: a systematic review of community-based participatory research to address health disparities in environmental and occupational health in the USA","volume":"62","author":"Cook WK","year":"2008","unstructured":"Cook WK. Integrating research and action: a systematic review of community-based participatory research to address health disparities in environmental and occupational health in the USA. J. Epidemiol. Community Health 62(8), 668\u2013676 (2008).","journal-title":"J. Epidemiol. Community Health"},{"issue":"1","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/1467-9566.13431","article-title":"What would it take to meaningfully attend to ethnicity and race in health research? Learning from a trial intervention development study","volume":"44","author":"Rai T","year":"2022","unstructured":"Rai T, Hinton L, McManus RJ, Pope C. What would it take to meaningfully attend to ethnicity and race in health research? Learning from a trial intervention development study. Sociol Health Illn. 44(S1), 57\u201372 (2022).","journal-title":"Sociol Health Illn."},{"issue":"1","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/1467-9566.13431","article-title":"What would it take to meaningfully attend to ethnicity and race in health research? Learning from a trial intervention development study","volume":"44","author":"Rai T","year":"2022","unstructured":"Rai T, Hinton L, McManus RJ, Pope C. What would it take to meaningfully attend to ethnicity and race in health research? Learning from a trial intervention development study. Sociol Health Illn. 44(S1), 57\u201372 (2022).","journal-title":"Sociol Health Illn."},{"issue":"2","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2307\/3562038","article-title":"False hopes and best data: consent to research and the therapeutic misconception","volume":"17","author":"Appelbaum PS","year":"1987","unstructured":"Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent. Rep. 17(2), 20\u201324 (1987).","journal-title":"Hastings Cent. Rep."},{"issue":"2","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3564231","article-title":"Therapeutic misconception in clinical research: frequency and risk factors","volume":"26","author":"Appelbaum PS","year":"2004","unstructured":"Appelbaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. IRB 26(2), 1\u20138 (2004).","journal-title":"IRB"},{"issue":"9","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"e0184224","DOI":"10.1371\/journal.pone.0184224","article-title":"Reducing therapeutic misconception: a randomized intervention trial in hypothetical clinical trials","volume":"12","author":"Christopher PP","year":"2017","unstructured":"Christopher PP, Appelbaum PS, Truong D, Albert K, Maranda L, Lidz C. Reducing therapeutic misconception: a randomized intervention trial in hypothetical clinical trials. PLOS ONE 12(9), e0184224 (2017).","journal-title":"PLOS ONE"},{"key":"e_1_3_8_39_2","volume-title":"The Psychology of Judgement and Decision-Making. (1st Edition)","author":"Plous S","year":"1993","unstructured":"Plous S. The Psychology of Judgement and Decision-Making. (1st Edition). McGraw-Hill, NY, USA (1993)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T10:24:58Z","timestamp":1721903098000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.57264\/cer-2023-0181"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0181","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2024,8]]},"article-number":"e230181"}}